<DOC>
	<DOCNO>NCT01757210</DOCNO>
	<brief_summary>Aprepitant approve 2003 . The drug work lessen amount nausea vomit cancer patient experience treatment . Aprepitant well-studied adult , child . Data adult study show aprepitant safe . It also show effective lessening amount nausea vomit adult patient experience . Because aprepitant show safe effective , investigator use pediatric patient hospital standard care . The investigator survey patient already receive aprepitant prevention chemotherapy-induced nausea vomit determine amount nausea vomit experience . The investigator also survey patient determine appetite like experience disruption activity daily live . The investigator also go assess side effect patient experience receive aprepitant .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Aprepitant ( MK0869 ) Chemotherapy-Induced Nausea Vomiting Pediatric Patients</brief_title>
	<detailed_description>This prospective , observational study conduct WVU Children´s Hospital . The study conduct one—year period data 20—40 patient encounter obtain . There randomization control group . Information collect patient meet study´s inclusion criterion . Patients give survey complete baseline , day chemotherapy , five day conclusion chemotherapy use BARF Scale 4—point Likert scale . The information collect survey include incidence severity nausea emesis , evaluation appetite , activity daily live , rescue medication use acute CINV . The specific chemotherapy regimen patient receives record . Any data identifying patient de—identified pertinent data collect . Descriptive statistic use analyze data .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>1 . Patient age 117 year 2 . Patient confirm malignancy 3 . Patient receive highly moderately emetogenic chemotherapy 4 . Receiving aprepitant part antiemetic regimen 5 . Patient 's legallyauthorized representative understands voluntarily sign write informed consent prior studyspecific procedure . A copy sign informed consent form retain treating institution . 6 . Patient ≥7 year age understand voluntarily sign write informed assent form prior study specific procedure . A copy sign informed assent form retain treating institution . Exclusion criterion : 1 . Pregnant breast feed 2 . Concomitant use pimozide , terfenadine , astemizole , cisapride 3 . ChildPugh score &gt; 9 4 . Receiving IV fosaprepitant</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Aprepitant</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Chemotherapy-induced nausea/vomiting</keyword>
	<keyword>Survey</keyword>
</DOC>